Turnaround time for COVID-19 test results
As the country’s need for COVID-19 testing evolves, Quest continues to monitor how turnaround times are affected by demand, supplies, and other factors. Stay up to date about when you can expect to get your results for COVID-19 active infection or antibody testing.
This page is updated frequently as testing turnaround times change. Last updated 11/09/2020.
Active infection testing
To diagnose whether you currently have an active COVID-19 infection, a sample must be collected through a nasal or throat swab. You may purchase an at-home collection kit or make an appointment at a drive-thru collection site through QuestDirect™. Another option is to reach out to your doctor or healthcare provider.
Quest then processes the samples in our lab and returns the results to you and your healthcare provider via MyQuest™. Tests for hospitalized patients, individuals in long-term care (such as nursing homes), and presurgical patients are prioritized ahead of tests for all other patients.
COVID-19 + flu testing
This test panel uses one sample to help you and your healthcare provider distinguish between flu and COVID-19 infections, since both illnesses have similar symptoms.
Contact your doctor or healthcare provider to be tested for an active COVID-19 infection and the flu. The sample is then sent to a Quest lab to be processed and the results are returned to you and your healthcare provider via MyQuest™.
This type of test detects antibodies that show if you have had a prior COVID-19 infection—even if you never experienced symptoms—and may possibly have a lower risk of reinfection. Quest draws your blood at a patient service center, and then processes the test in our lab. The results are sent to you and your healthcare provider.
Important information about COVID-19 antibody testing
The test is designed to detect antibodies to SARS-CoV-2, the virus that causes COVID-19. Antibodies are proteins that the body produces in response to infections. The antibodies can be produced even if a person has few or no symptoms during the infection.
It generally takes some time after infection for antibodies to be produced and become detectable in blood (sometimes up to 3 weeks). It is important to remember that we do not yet know whether having antibodies to SARS-CoV-2 will prevent against getting the infection again or if you are totally free of the virus. Antibodies are generally detectable in the blood for a period of time after a person has recovered from the infection and after the virus that caused the infection is no longer detectable by laboratory methods.
Sometimes the antibodies developed in response to an infection protect us from getting that same infection again. But, it is important to know that we do not yet know whether this is true for COVID-19. Even if you have recovered and have antibodies, there is a chance that you still have the virus and you can infect others, it is still critical to keep taking measures to avoid getting infected again and/or spreading infection.
The antibody test is not meant for detecting an active infection. The swab test (sometimes also known as a molecular, RNA or PCR test) should be used to test for active infection.
A negative antibody test result means that antibodies were not detected in your blood sample. This can have several possible meanings. It could mean that:
- You have not been infected with SARS-CoV-2, or
- You have been infected with SARS-CoV-2, but your antibodies have not reached a sufficient level for the test to be able to detect them, or
- You have been infected with SARS-CoV-2, but there has not been enough time for antibodies to develop (it can take up to one to three weeks to develop antibodies after someone is infected, sometimes longer).
A positive antibody test result means that antibodies were detected in your blood sample. This can have a couple of possible meanings. It could mean that:
- You have been infected with SARS-CoV-2 at some point in the past, or
- Uncommonly, you may have developed antibodies from an earlier infection with a different virus related to SARS-CoV-2 and the laboratory test cannot distinguish between these other virus antibodies and those antibodies generated in response to SARS-CoV-2.
COVID-19 testing statements
- The antibody tests have not been FDA cleared or approved;
- The antibody tests have been authorized by FDA under an EUA for use by authorized laboratories;
- The antibody tests have been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens; and,
- The antibody tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
- The cobas SARS-CoV-2 & Influenza A/B Test and the Quest SARS-CoV-2 RT-PCR test and other molecular tests (“Tests”) have not been FDA cleared or approved.
- The tests have been authorized by the FDA under an EUA for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform moderate and high complexity tests. The Roche test has been authorized only for the detection of RNA from SARS-CoV-2 virus, Influenza A virus, and Influenza B virus and not any other viruses or pathogens.
- The Roche test is only authorized for the duration of the declaration that circumstances exist justifying the authorized of the emergency use of in vitro diagnostics for detection and differentiation of SARS-CoV-2 virus, Influenza A, and Influenza B under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the authorized is terminated or revoked sooner.
- The Quest test and other molecular tests been authorized only for the detection of nucleic acid from SARSCoV-2, not for any other viruses or pathogens.
- The Quest test and other molecular tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.